On ECHEMI
Home > Drugs > Yuanda Shuyang Life Science (Chengdu) Co., Ltd.
Yuanda Shuyang Life Science (Chengdu) Co., Ltd.
  • Founded in:

    1985-08-12
  • Country:

    China China
  • Address:

    No. 888, Antai 5th Road, Chengdu Hi-tech Zone
  • Tax NO.:

    91510100202368620M
  • Registered Funds:

    320 million yuan
  • Email:

Related Drugs
Hepatitis B immune globulin
Molecular weight of human hepatitis B immunoglobulin.
Name Description Content CAS NO. Registered Holders
Human Hepatitis B immunoglobulin BRP

This product contains high titer hepatitis B surface antibodies, which can specifically bind to the corresponding antigen to play a role in passive immunity

More

This product contains high titer hepatitis B surface antibodies, which can specifically bind to the corresponding antigen to play a role in passive immunity

0
Histamine human immunoglobulin
Main ingredients: human immunoglobulin, histamine phosphate or histamine hydrochloride.
Name Description Content CAS NO. Registered Holders
human immunoglobulin

Stimulate the body to produce anti-histamine antibodies, thereby eliminating the pathogenic effects of endogenous histamine

More

Stimulate the body to produce anti-histamine antibodies, thereby eliminating the pathogenic effects of endogenous histamine

0
Histamine phosphate

Stimulate the body to produce anti-histamine antibodies, thereby eliminating the pathogenic effects of endogenous histamine

More

Stimulate the body to produce anti-histamine antibodies, thereby eliminating the pathogenic effects of endogenous histamine

51-74-1 0
Histamine dihydrochloride

Stimulate the body to produce anti-histamine antibodies, thereby eliminating the pathogenic effects of endogenous histamine

More

Stimulate the body to produce anti-histamine antibodies, thereby eliminating the pathogenic effects of endogenous histamine

56-92-8 6
Intravenous human immunoglobulin (pH4)
Main ingredients: Human immunoglobulin
Name Description Content CAS NO. Registered Holders
human immunoglobulin

Immunoglobulin injection is a passive immunotherapy. It is to transfer a large amount of antibodies contained in immunoglobulin to the recipient, so that the recipient can quickly reach a temporary immune protection state from a low or no immune state. Because antibodies and antigens interact with each other to directly neutralize toxins and kill bacteria and viruses. Therefore, immunoglobulin products have a certain effect on preventing bacterial and viral infections.

More

Immunoglobulin injection is a passive immunotherapy. It is to transfer a large amount of antibodies contained in immunoglobulin to the recipient, so that the recipient can quickly reach a temporary immune protection state from a low or no immune state. Because antibodies and antigens interact with each other to directly neutralize toxins and kill bacteria and viruses. Therefore, immunoglobulin products have a certain effect on preventing bacterial and viral infections.

0
Intravenous human immunoglobulin (pH4)
Main components: More than 95% of the protein in this product is immunoglobulin.
Name Description Content CAS NO. Registered Holders
IMMUNOGLOBULIN G FROM MOUSE SERUM*

This product contains broad-spectrum IgG antibodies against viruses, bacteria or other pathogens. In addition, the unique type of immunoglobulin and the unique type antibody form a complex immune network, so it has the dual therapeutic effects of immune replacement and immune regulation. After intravenous infusion, it can quickly increase the IgG level in the recipient's blood and enhance the body's anti-infection ability and immune regulation function.

More

This product contains broad-spectrum IgG antibodies against viruses, bacteria or other pathogens. In addition, the unique type of immunoglobulin and the unique type antibody form a complex immune network, so it has the dual therapeutic effects of immune replacement and immune regulation. After intravenous infusion, it can quickly increase the IgG level in the recipient's blood and enhance the body's anti-infection ability and immune regulation function.

0
Intravenous hepatitis B human immune globulin (pH4)
Hepatitis B human immunoglobulin, excipient: maltose.
Name Description Content CAS NO. Registered Holders
Hepatitis B immune globulin

Contains high titer anti-HBs, which can specifically bind to HBsAg and play a role in passive immunity. It may protect liver cells from infection by blocking HBV receptors, or neutralize viral particles in the circulating blood in the form of immune complexes, triggering antibody-dependent leukocyte-mediated toxic reactions and then killing target cells and causing lysis.

More

Contains high titer anti-HBs, which can specifically bind to HBsAg and play a role in passive immunity. It may protect liver cells from infection by blocking HBV receptors, or neutralize viral particles in the circulating blood in the form of immune complexes, triggering antibody-dependent leukocyte-mediated toxic reactions and then killing target cells and causing lysis.

0
Maltose

Pharmacological action: This product contains high titer anti-HBs, which can specifically bind to HBsAg and play a role in passive immunity. Its mechanism of action is not very clear. It may protect liver cells from infection by blocking HBV receptors, or it may neutralize viral particles in the circulating blood in the form of immune complexes, triggering antibody-dependent leukocyte-mediated toxic reactions and then killing target cells and causing lysis. Toxicological studies: The results of preclinical animal tests of this product are as follows: 1. The results of general pharmacology studies showed that the use of 800, 1600, and 3200 IU/kg dosing groups and a single intravenous administration had no significant effect on the general mental state, behavioral activities, central nervous system and digestive system of mice; the use of 350,

More

Pharmacological action: This product contains high titer anti-HBs, which can specifically bind to HBsAg and play a role in passive immunity. Its mechanism of action is not very clear. It may protect liver cells from infection by blocking HBV receptors, or it may neutralize viral particles in the circulating blood in the form of immune complexes, triggering antibody-dependent leukocyte-mediated toxic reactions and then killing target cells and causing lysis. Toxicological studies: The results of preclinical animal tests of this product are as follows: 1. The results of general pharmacology studies showed that the use of 800, 1600, and 3200 IU/kg dosing groups and a single intravenous administration had no significant effect on the general mental state, behavioral activities, central nervous system and digestive system of mice; the use of 350,

69-79-4 10
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.